Pathogenesis and immune response in tuberculous meningitis

Malaysian Journal of Medical Sciences

Volumn 21, Issue 1, 2014, Pages 4-10

  Isabel, Bini Estela ^a   Rogelio, Hernández Pando ^a,b  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b SCHOOL OF MEDICAL SCIENCES   (Malaysia)

Author keywords

Cerebrospinal fluid; Tuberculosis; Tuberculous meningitis

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; BACTERIAL IMMUNITY; BACTERIUM ISOLATION; BLOOD BRAIN BARRIER; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM TUBERCULOSIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; DISEASE MODEL; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INFECTION RISK; INFLAMMATION; LUNG TUBERCULOSIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MONOCYTE; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; REVIEW; T LYMPHOCYTE; TUBERCULOUS MENINGITIS;

EID: 84902441290     PISSN: 1394195X     EISSN: 21804303     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Rook GAW, Hernández Pando R. The pathogenesis of tuberculosis. Annual Rev Microbiol. 1996; 50: 259-284. doi: 10. 1146/annurev. micro. 50. 1. 259.
2. WHO Global Health Organization. TB-a global emergency. WHO report on the TB epidemic. Geneva (CH): World Health Organization; 1994.
3. Garg RK. Tuberculosis of the central nervous system. Postgrad Med J. 1999; 75(881): 133-140.
4. Katti MK. Pathogenesis, diagnosis, treatment, and outcome aspects of cerebral tuberculosis. Med Sci Monit. 2004; 10(9): RA215-229.
5. Maltezou HC, Spyridis P, Kafetzis DA. Extrapulmonary tuberculosis in children. Arch Dis Child. 2000; 83(4): 342-346.
6. Ogawa SK, Smith MA, Brennessel DJ, Lowry FD. Tuberculous meningitis in an urban medical centre. Medicine. 1987; 66(4): 317-326.
7. Jaffe IP. Tuberculous meningitis in childhood. Lancet. 1982; 1(8274): 738.
8. Parsons M. Tuberculous meningitis. Oxford (UK): Oxford University Press; 1979. p. 2-4.
9. Rich AR, McCordock HA. The pathogenesis of tubercular meningitis. Bull John Hopkins Hosp. 1933; 52: 5-13.
10. Hernández PR, Aguilar D, Cohen I, Guerrero M, Ribon W, Acosta P, et al. Specific bacterial genotype of Mycobacterium tuberculosis cause extensive dissemination and brain infection in an experimental model. Tuberculosis (Edinb). 2010; 90(4): 268-277. doi: 10. 1016/j. tube. 2010. 05. 002.
11. Huang SH, Jong AY. Cellular mechanisms of microbial proteins contributing to invasion of the blood-brain barrier. Cell Microbiol. 2001; 3(5): 277-287.
12. Jain SK, Paul-Satyassela M, Lamichhane G, Kim KS, Bishai WR. Mycobacterium tuberculosis invasion and traversal across an in vitro human blood-brain barrier as a pathogenic mechanism for central nervous system tuberculosis. J Infect Dis. 2006; 193(9): 1287-1295.
13. Arvanitakis Z, Long RL, Herschfield ES, Manfreda J, Kabani A, Kunimoto D, et al. M. tuberculosis molecular variation in CNS infection: Evidence for strain-dependent neurovirulence. Neurology. 1998; 50(6): 1827-1832.
14. Menozzi F, Biochoff R, Fort E, Brennan M, Locht C. Molecular characterization of the mycobacterial heparin binding hemaglutanina mycobacterial adhesin. Proc Natl Acad Sci USA. 1998; 95(21): 12625-12630.
15. Soares de LC, Zulianello L, Melo Marques M, Kim H, Portugal MI, Antunes SL, et al. Mapping the laminin-binding and adhesive domain of the cell surface-associated Hlp/LBP protein from Mycobacterium leprae. Microbes Infect. 2005; 7(9-10): 1097-1109.
16. de Vries HE, Kuiper J, de Boer AG, Van Berkel TJ, Breimer DD. The blood-brain barrier in neuroinflammatory diseases. Pharmacol Rev. 1997; 49(2): 143-155.
17. de Vries HE, Blom-Roosemalen MC, van Oosten M, de Boer AG, van Berkel TJ, Breimer DD, et al. The influence of cytokines on the integrity of the blood-brain barrier in vitro. J Neuroimmunol. 1996; 64(1): 37-43.
18. Plata-Salamán CR. Immunoregulators in the nervous system. Neurosci Biobehav Rev. 1991; 15(2): 185-215.
19. Banks WA, Ortiz L, Plotkin SR, Kastin AJ. Human interleukin (IL) 1alpha, murine interleukin-1alpha and murine interleukin-1beta are transported from blood to brain in the mouse by a shared saturable mechanism. J Pharmacol Exp Ther. 1991; 259(3): 988-996.
20. Kleinnijenhuis J, Oosting M, Joosten LA, Netea MG, Van Crevel R. Innate immune recognition of Mycobacterium tuberculosis. Clin Dev Immunol. 2011; 2011: 405310. doi: 10. 1155/2011/405310.
21. Rivas Santiago B, Sada E, Tsutsumi V, Aguilar Leon D, Leon Contreras JC, Hernández Pando R. β-Defensin gene expression during the course of experimental tuberculosis infection. J Infect Dis. 2006; 194(5): 697-701.
22. Behar SM, Divangahi M, Remold HG. Evasion of innate immunity by Mycobacterium tuberculosis: is death an exits strategy? Nat Rev Microbiol. 2010; 8(9): 668-674. doi: 10. 1038/nrmicro2387.
23. Rios Barrera V, Campos Peña V, Aguilar Leon D, Lascurain Ledesma R, Meraz Rios MA, Moreno J, et al. Macrophage and T lymphocyte apoptosis during experimental pulmonary tuberculosis: Their relationship to mycobacterial virulence. Eur J Immunol. 2006; 36(2): 345-353.
24. Hernández-Pando R, Orozco H, Aguilar D. Factors that deregulate the protective immune response in tuberculosis. Arch Immunol Ther Exp (Warsz). 2009; 57(5): 355-367. doi: 10. 1007/s00005-009-004 2-9.
25. Mastroianni CM, Paoletti F, Lichtner M, DÁgostino C, Vullo V, Delia S. Cerebrospinal fluid cytokines in patients with tuberculous meningitis. Clin Immunol Immunopathol. 1997; 84(2): 171-176.
26. Babu GN, Kumar A, Kalita J, Misra UK. Pro-inflammatory cytokines levels in the serum and cerebrospinal fluid of tuberculous meningitis patients. Neuroscience Lett. 2008; 436(1): 48-51. doi: 10. 1016/j. neulet. 2008. 02. 060.
27. Misra UK, Kalita J, Srivastava R, Nair PP, Mishra MK, Basu A. A study of cytokines in tuberculous meningitis: Clinical and MRI correlation. Neurosci Lett. 2010; 483(1): 6-10. doi: 10. 1016/j. neulet. 2010. 07. 029.
28. Mansour AM, Frenck RW Jr, Darville T, Nakhla IA, Wierzba TF, Sultan Y, et al. Relationship between intracranial granulomas and cerebrospinal fluid levels of gamma interferon and interleukin-10 in patients with tuberculous meningitis. Clin Diagn Lab Immunol. 2005; 12(2): 363-365.
29. Tobin DM, Roca FJ, Oh SF, McFarland R, Vickery TW, Ray JP, et al. "Host genotypespecific therapies can optimize the inflammatory response to mycobacterial infections". Cell. 2012; 148(3): 434-446. doi: 10. 1016/j. cell. 2011. 12. 023.
30. Vanden Driessche K, Persson A, Marais BJ, Fink PJ, Urdahl KB. Immune vulnerability of infants to Tuberculosis. Clin Dev Immunol. 2013; 2013; 781320. doi: 10. 1155/2013/781320.
31. Akalin H, Akdis AC, Mistik R, Helvaci S, Kilicturgay K. Cerebrospinal fluid interleukin-1 beta/interleukin-1 receptor antagonist balance and tumor necrosis factor-alpha concentrations in tuberculous, viral and acute bacterial meningitis. Scand J Infect Dis. 1994; 26(6): 667-674.
32. Mastroianni CM, Lancella L, Mengoni F, Lichtner M, Santopadre P, D'Agostino C, et al. Chemokine profiles in the cerebrospinal fluid (CSF) during the course of pyogenic and tuberculous meningitis. Clin Exp Immunol. 1998; 114(2): 210-214.
33. Chen L, Jiang H, Wei C. Nitric oxide, TNF-alpha and IL-8 in cerebrospinal fluids of tuberculous and cryptococcic meningitis. Hunan Yi Ke Da Xue Xue Bao. 1997; 22(6): 514-516.
34. Tsenova L, Bergtold A, Freedman VH, Young RA, Kaplan G. Tumor necrosis factor alpha is a determinant of pathogenesis and disease progression in mycobacterial infection in the central nervous system. Proc Natl Acad Sci USA. 1999; 96(10): 5657-5662.
35. Tsenova L, Sokol K, Freedman VH, Kaplan G. A combination of thalidomide plus antibiotics protect rabbits from mycobacterial meningitis-associated death. J Infect Dis. 1998; 177(6): 1563-1572.
36. Zucchi FCR, Pelegrini-da-Silva A, Neder L, Silva CL, Tsanaclis AMC, Takayanagui OM. The contribution of a murine CNS-TB model for the understanding of the host-pathogen interactions in the formation of granulomas. J Neurosci Methods. 2012; 206(1): 88-93. doi: 10. 1016/j. jneumeth. 2012. 02. 015.
37. Hendrix S, Nitsch R. The role of T helper cells in neuroprotection and regeneration. J Neuro Immunol. 2007; 184(1-2): 100-112.
38. Schoeman JF, Fieggen G, Seller N, Mendelson M, Hartzenberg B. Intractable intracranial tuberculous infection responsive to thalidomide: report of four cases. J Child Neurol. 2006; 21(4): 301-308.
39. Cheng VC, Yam WC, Woo PC, Lau SK, Hung IF, Wong SP, et al. Risk factors for development of paradoxical response during anti-tuberculous therapy in HIV-negative patients. Eur J Clin Microbiol Infect Dis. 2003; 22(10): 597-602.
40. Conradie F, Foulkes AS, Ive P, Yin X, Roussos K, Glencross DK, et al. Natural Killer cell activation distinguishes Mycobacterium tuberculosis-mediated immune reconstitution syndrome from chronic HIV and HIV/MTB coinfection. J Acquir Immune Defic Syndr. 2011; 58(3): 309-318.
41. Haddow LJ, Dibben O, Moosa MY, Borrow P, Easterbrook PJ. Circulating inflammatory biomarkers can predict and characterize tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS. 2011; 25(9): 1163-1174. doi: 10. 1097/QAD. 0b0 13e3283477d67.
42. de Almeida AS, Fiske CT, Sterling TR, Kalams SA. Increased frequency of regulatory T cells and T lymphocyte activation in persons with previously treated extrapulmonary tuberculosis. Clin Vaccine Immunol. 2012; 19(1): 45-52. doi: 10. 1128/CVI. 052 63-11.
43. Saenz B, Hernandez-Pando R, Fragoso G, Bottasso O, Cárdenas G. The dual face of central nervous system tuberculosis: a new Janus Bifrons? Tuberculosis (Edinburgh). 2013: 93(2): 130-135.
44. Blackmore TK, Manning L, Taylor WJ, Wallis RS. Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin Infect Dis. 2008; 47(10): e83-85. doi: 10. 1086/592695.